Diabetes and obesity - Issue 2/2025
Editorial
Original paper
78
Where do we stand in controlling dyslipidemia in patients with type 2 diabetes mellitus? Retrospective analysis 2019–2023
Jozef Lacka, Petra Ištokovičová, Martin Jankovský, Peter Jackuliak, Elena Tibenská
Reviews
89
Patients with T1D and high CV risk show pathological T1 time values and an increased percentage of extracellular myocardial volume on cardiac MRI
Peter Novodvorský, Michal Dubský, Natália Marhefková, Theodor Adla, Robert Roland, Michal Pazderník, Martin Haluzík, Pankaj Garg
95
Meformin and predictive biomarkers in the broad spectrum of internal diseases
Andrej Dukát, Juraj Payer, Peter Jackuliak, Hana Štefaničková, Ján Kyselovič, Andrea Gažová, Martin Jankovský, Samuel Nachtmann, Patrik Valent, Juraj Smaha
102
Steroid (glucocorticoids) induced hyperglycemia and diabetes
Vladimír Uličiansky, Zbynek Schroner
109
News
125
14-week program: online coaching for patients with obesity
Barbara Ukropcová, Emília Beblavá, Zuzana Košutzká, Jozef Ukropec, Miroslav Beblavý
127
SURPASS-CVOT Study: comment
Zbynek Schroner
129
History and uniqueness of the original metformin XR
Katarína Černá
News
132
133
137
141
61st EASD Congress, 15.–19. september 2025, Vienna: what caught our attention the most
Katarína Langová, Gabriela Švrčková
Personalities
Diabetes and obesity
2025 Issue 2
Most read in this issue
- Development and possibilities of contemporary outpatient diabetology: editorial
- 14-week program: online coaching for patients with obesity
- IDF World Diabetes Congress, April 7–10, 2025, Bangkok: Slovakia‘s footprint at an international event
- Report from the EAsDEC 2025 Congress, Liverpool, June 5–7, 2025: Slovakia‘s voice at the European forum on diabetic eye complications – challenges, evidence, and opportunities at the crossroads of research and practice